Safety and clinical activity of oleclumab (O) ± durvalumab (D) plus chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A phase 1b/2 randomized study

被引：0

作者：

Coveler, Andrew L.

Reilley, Matthew

Zalupski, Mark

Macarulla, Teresa

Fountzilas, Christos

Castanon Alvarez, Eduardo

Nagrial, Adnan

Volodymyrivna Uboha, Nataliya

Frentzas, Sophia

Overman, Michael J.

Noonan, Anne M.

Messersmith, Wells A.

Pavlakis, Nick

Mettu, Niharika B.

Smith, Paul

Murtomaki, Elina

Bragulat, Veronique

Cooper, Zachary A.

Kumar, Rakesh

Spigel, David

机构：

[1] Fred Hutchinson Canc Ctr, Seattle, WA USA

[2] Univ Virginia, Ctr Comprehens Canc, Charlottesville, VA USA

[3] Univ Michigan Hlth Syst, Ann Arbor, MI USA

[4] Hosp Univ Vall DHebron, Barcelona, Spain

[5] Roswell Pk Canc Inst, Buffalo, NY USA

[6] Clin Univ Navarra, Madrid, Spain

[7] Blacktown Hosp, Sydney, NSW, Australia

[8] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[9] Monash Hlth Monash Med Ctr, Clayton, Vic, Australia

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[11] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH USA

[12] Univ Colorado, Denver, CO USA

[13] Royal North Shore Hosp, Northern Sydney Canc Ctr, Sydney, NSW, Australia

[14] Duke Univ, Med Ctr, Durham, NC USA

[15] AstraZeneca, Cambridge, England

[16] AstraZeneca, Gaithersburg, MD USA

[17] Sarah Cannon Res Inst, Nashville, TN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 50 条

[41] Phase 1 study of anti-immunoglobulin-like transcript 3 (ILT3) monoclonal antibody MK-0482+pembrolizumab plus gemcitabine plus nab-paclitaxel (Gem/Nab-P) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).
Golan, Talia
Cohen, Jonathan
Voskoboynik, Mark
Gutierrez, Martin
Park, John J.
Valente, Monica
Renouf, Daniel John
Liu, Qi
Edmondson, Mackenzie
Myer, Nicole
Kapadia, Kishan J.
Chen, Mei
Victoria, Ivan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[42] Real life triplet FIr/FOx chemotherapy in first line metastatic pancreatic ductal adenocarcinoma: Recommended schedule for expected activity and safety and phase II study
Bruera, G.
Massacese, S.
Manetta, R.
Giordano, A.
Carducci, S.
Ciacco, E.
Ricevuto, E.
ANNALS OF ONCOLOGY, 2018, 29 : 43 - 43
[43] Safety and preliminary activity of naptumomab estafenatox (NAP) and durvalumab in patients with advanced or metastatic solid tumors: interim results from a phase 1b trial
Geva, Ravit
Stemmer, Salomon
Perets, Ruth
Maurice-Dror, Corinne
Ben-Ami, Eitan
Raphael, Ari
Kumar, Sanjeev
Lorber, Ilana
Kedem, Tal Hetzroni
Fields, Scott Z.
Rozencweig, Marcel
Golan, Talia
CANCER RESEARCH, 2023, 83 (08)
[44] ARC-8: Phase I/Ib study to evaluate safety and tolerability of AB680+chemotherapy plus zimberelimab (AB122) in patients with treatment-naive metastatic pancreatic adenocarcinoma (mPDAC).
Manji, Gulam Abbas
Wainberg, Zev A.
Krishnan, Kartik
Giafis, Nick
Udyavar, Akshata
Quah, Cheng Seok
Scott, Jennifer
Berry, Wade
DiRenzo, Daniel
Gerrick, Kimberline
Jin Lixia
Bendell, Johanna C.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[45] A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Chang, Chen
Li, Xiaofen
Cheng, Ke
Cai, Zhaolun
Xiong, Junjie
Lv, Wanrui
Li, Ruizhen
Zhang, Pei
Cao, Dan
ONCOLOGIST, 2023, 28 (07): : E575 - E584
[46] CD40 agonist mitazalimab combined with mFOLFIRINOX (mFFX) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Primary analysis of the OPTIMIZE-1 phase Ib/II study
Macarulla Mercade, T.
Borbath, I.
Geboes, K.
Lambert, A.
Cassier, P.
Prenen, H.
Mitry, E.
Blanc, J. F.
Pilla, L.
Feliu, J.
Rodriguez, M.
Cid, R. A. Pazo
Gallego Jimenez, I.
Gomez Jimenez, D.
Smith, K. E.
Nordbladh, K.
Ellmark, P.
Pico de Coana, Y.
Ambarkhane, S. V.
van Laethem, J-L.
ANNALS OF ONCOLOGY, 2024, 35 : S118 - S118
[47] Preliminary results of a phase II study of surufatinib plus sintilimab, nab-paclitaxel and gemcitabine (AG) as first-line therapy in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (mPDAC).
Zhang, Dong-Sheng
Liu, Fu-Rong
Lu, Yun-Xin
Bai, Bing
Zhang, Yang
Wang, Zhi-Qiang
Liu, Yu
Chen, Jian-Wen
Wang, Feng
Xu, Rui-Hua
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 659 - 659
[48] Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study
Chen, L-T.
Macarulla Mercade, T.
Lee, K-H.
Lakatos, G.
Wang-Gillam, A.
Mirakhur, B.
de Jong, F.
ANNALS OF ONCOLOGY, 2018, 29
[49] Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors
Stradella, Agostina
Johnson, Melissa
Goel, Sanjay
Park, Haeseong
Lakhani, Nehal
Arkenau, Hendrik-Tobias
Galsky, Matthew D.
Calvo, Emiliano
Baz, Vicente
Moreno, Victor
Saavedra, Omar
Luen, Stephen J.
Mu, Song
Wan, Qiting
Chang, Victoria
Zhang, Wa
Barve, Minal
CANCER MEDICINE, 2024, 13 (13):
[50] A phase I study of gemcitabine/nab-paclitaxel/S-1 chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
Chang, Chen
Li, Xiaofen
Cheng, Ke
Cai, Zhaolun
Xiong, Junjie
Lv, Wanrui
Li, Ruizhen
Zhang, Pei
Cao, Dan
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16261 - E16261

← 1 2 3 4 5 →